ADAGIO MEDICAL HOLDINGS, INC.

EDGAR

Annual consolidated revenue for 2025: about USD 0, using the latest filing vintage with reviewed corrections applied. Corrected values apply reviewed corrections and remain separate from issuer reports. The previous period, 2023, was about USD 300K.

Watchlist

Holdings and insider activity

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.

Window: transactions dated on or after 2025-11-19.

Open-market purchases (code P)
2 transactions, 222,315 shares
Sum of shares × price per share: 243,946.35
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

  • 2026-06-16 Salmon Sean A 30,000 0
  • 2026-06-16 Cox James L A 30,000 0
  • 2026-06-16 GARDINER SANDRA A. A 30,000 0
  • 2026-06-16 MISHAN ORLY A 100,000 0
  • 2026-06-16 Mirsaeedi-Farahani Keyvan A 30,000 0

5% holders (Schedule 13D and 13G)

  • Perceptive Advisors LLC 44.4% SCHEDULE 13G/A 09/30/2026
  • Joseph Edelman 44.4% SCHEDULE 13G/A 09/30/2026
  • Perceptive Life Sciences Master Fund, Ltd. 43.9% SCHEDULE 13G/A 09/30/2026

See all insider transactions

Short annual reporting periods

These figures cover less than a full year. They are not annualized and are excluded from full-year trends and comparisons.

Corrected figures
MeasurePeriodValue
Net income2024-08-01 – 2024-12-31-53763000 USD Source Dispute
Capital expenditure2024-01-01 – 2024-07-30368000 USD Source Dispute
Cost of revenue2024-01-01 – 2024-07-301381000 USD Source Dispute
Gross profit2024-01-01 – 2024-07-30-1048000 USD Source Dispute
Net income2024-01-01 – 2024-07-30-21300000 USD Source Dispute
Operating cash flow2024-01-01 – 2024-07-30-15990000 USD Source Dispute
Operating income2024-01-01 – 2024-07-30-21680000 USD Source Dispute
Research and development2024-01-01 – 2024-07-307585000 USD Source Dispute
Revenue2024-01-01 – 2024-07-30333000 USD Source Dispute
Selling, general and administrative2024-01-01 – 2024-07-3013047000 USD Source Dispute

Latest quarter

Revenue

0 USD

2026 Q3 · USD

Exact inputs and evidence

Operating cash flow

-4.6 million USD

2026 Q3 · USD

Exact inputs and evidence
  • Operating Cash Flow: -14000000 USD Source
  • Operating Cash Flow: -9400000 USD Source

Free cash flow

-4.6 million USD

2026 Q3 · USD

Exact inputs and evidence
  • Operating Cash Flow: -14000000 USD Source
  • Operating Cash Flow: -9400000 USD Source
  • Capital Expenditure: 12000 USD Source
  • Capital Expenditure: 8000 USD Source
Cash and cash equivalents
3.1 million USD Source
Exact value

3100000 USD

Long-term debt including current maturities
2.01 million USD
Exact inputs and evidence

2010000 USD

  • Long-term debt including current maturities: 2010000 USD Source
Shares outstanding
890 thousand shares Source
Exact value

889644 shares

Reported share-count change

-94.22% · -14.5 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence
  • 15381565 shares · 2025-09-30· Source
  • 889644 shares · 2026-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2025-10-01 – 2026-09-30

Exact inputs and evidence
  • Revenue: 0 USD · 2025-01-01 – 2025-12-31 Source
  • Revenue: 0 USD · 2025-01-01 – 2025-09-30 Source
  • Revenue: 0 USD · 2026-01-01 – 2026-03-31 Source
  • Revenue: 0 USD · 2026-04-01 – 2026-06-30 Source
  • Revenue: 0 USD · 2026-07-01 – 2026-09-30 Source

Net income

818 thousand USD

2025-10-01 – 2026-09-30

Exact inputs and evidence
  • Net income: -25100000 USD · 2025-01-01 – 2025-12-31 Source
  • Net income: -21778000 USD · 2025-01-01 – 2025-09-30 Source
  • Net income: -7000000 USD · 2026-01-01 – 2026-03-31 Source
  • Net income: -6700000 USD · 2026-04-01 – 2026-06-30 Source
  • Net income: 17840000 USD · 2026-07-01 – 2026-09-30 Source

Company performance

Up to ten complete financial years · consolidated figures

Latest filing vintage with reviewed corrections applied; these values remain separate from issuer-reported figures. Annual charts exclude incomplete years.

Latest filing recorded: 2026-11-16.

Financial data available through: 2025-12-31.

Coverage by financial measure
  • Revenue: 2 of 11 periods available· newest 2025-12-31
  • Operating income: 2 of 11 periods available· newest 2025-12-31
  • Net income: 2 of 11 periods available· newest 2025-12-31
  • Operating cash flow: 2 of 11 periods available· newest 2025-12-31
  • Capital expenditure: 2 of 11 periods available· newest 2025-12-31
  • Total assets: 2 of 11 periods available· newest 2025-12-31
  • Total liabilities: 2 of 11 periods available· newest 2025-12-31
  • Current assets: 2 of 11 periods available· newest 2025-12-31
  • Current liabilities: 2 of 11 periods available· newest 2025-12-31
  • Cash and cash equivalents: 2 of 11 periods available· newest 2025-12-31
  • Long-term debt including current maturities: 2 of 11 periods available· newest 2025-12-31
  • Shares outstanding: 2 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

No unambiguous prior-year comparison is available for the latest reporting period.

Comparable inputs unavailable for: Revenue, Net income, Operating cash flow, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

  • Revenue USD 0
  • Cost of revenue USD 684,000
  • Operating expenses USD 21.21 million
  • Other operating costs Derived USD 0
  • Operating income −USD 21.89 million
  • Tax, interest and other Derived USD 3.21 million
  • Net income −USD 25.1 million

Cash

  • Operating cash flow −USD 19.01 million
  • Capital expenditure USD 374,000
  • Free cash flow Derived −USD 19.39 million

Share of revenue by period

  • Net income
  • Tax, interest and other
  • Operating costs
  • 2023 Operating loss: operating costs were 9,414% of revenue.
  • 2025 Not shown: operating income or net income is not reported.
Values and sources
Revenue breakdown by annual reporting period
PeriodRevenueOperating costsOperating incomeTax, interest and otherNet incomeFree cash flowSource
2023 2023-01-01 – 2023-12-31300000 28242000 Derived -27942000 8658000 Derived -36600000 -26033000 Derived
Source
2025 2025-01-01 – 2025-12-310 21890000 Derived -21890000 3210000 Derived -25100000 -19388000 Derived
Source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2025
Revenue historyRevenue reported for each complete financial period. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.324.0K243.0K162.0K81.0K0.020232025
Values and sources
Revenue values and source evidence
PeriodSeriesValue(USD)Source evidence
2023Revenue300000
2025Revenue0

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.
Values and sources
Revenue growth values and source evidence
PeriodSeriesValueSource evidence
2023Year over yearNo prior comparable period
2025Year over yearNo prior comparable period

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -9,314% 2023
Net margin -12,200% 2023
Free cash flow margin -8,677.7% 2023
Profit margins historyOperating income, net income and free cash flow as a share of revenue. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.976%-2,562%-6,100%-9,638%-13,176%20232025
  • Operating margin
  • Net margin
  • Free cash flow margin
Values and sources
Profit margins values and source evidence
PeriodSeriesValueSource evidence
2023Operating margin-9,314%
2025Operating marginNot reported
2023Net margin-12,200%
2025Net marginNot reported
2023Free cash flow margin-8,677.7%
2025Free cash flow marginNot reported

Operating cash flow

Cash generated by the company’s normal business operations.

USD -19M 2025
Operating cash flow historyCash generated by the company’s normal business operations. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.2.1M-5.4M-12.9M-20.3M-27.8M20232025
Values and sources
Operating cash flow values and source evidence
PeriodSeriesValue(USD)Source evidence
2023Operating cash flow-25700000
2025Operating cash flow-19014000

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -19.4M 2025
Free cash flow historyOperating cash flow minus capital expenditure for the same period and unit. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.2.1M-5.5M-13.0M-20.6M-28.1M20232025
Values and sources
Free cash flow values and source evidence
PeriodSeriesValue(USD)Source evidence
2023Free cash flow-26033000
2025Free cash flow-19388000

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

71.3% 2025
Liabilities to assets historyTotal liabilities as a share of total assets. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.750%562%375%187%0%20232025
Values and sources
Liabilities to assets values and source evidence
PeriodSeriesValueSource evidence
2023Liabilities / assets694.2%
2025Liabilities / assets71.3%

Current assets to current liabilities

Current assets divided by current liabilities.

2.44× 2025
Current assets to current liabilities historyCurrent assets divided by current liabilities. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.2.63×1.98×1.32×0.66×0.00×20232025
Values and sources
Current assets to current liabilities values and source evidence
PeriodSeriesValueSource evidence
2023Current assets / current liabilities0.11×
2025Current assets / current liabilities2.44×

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
PeriodNet incomeOperating cash flowCapital expenditureFree cash flow
2023 2023-01-01 – 2023-12-31
−USD 36.6 million
Exact value

Exact value: -36600000 USD

2023-01-01 – 2023-12-31: -36600000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 25.7 million
Exact value

Exact value: -25700000 USD

2023-01-01 – 2023-12-31: -25700000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 333,000
Exact value

Exact value: 333000 USD

2023-01-01 – 2023-12-31: 333000 USD Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 26.03 million
Calculation and evidence

-25700000 − 333000 USD

Exact free cash flow: -26033000 USD

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2025 2025-01-01 – 2025-12-31
−USD 25.1 million
Exact value

Exact value: -25100000 USD

2025-01-01 – 2025-12-31: -25100000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 19.01 million
Exact value

Exact value: -19014000 USD

2025-01-01 – 2025-12-31: -19014000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 374,000
Exact value

Exact value: 374000 USD

2025-01-01 – 2025-12-31: 374000 USD Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 19.39 million
Calculation and evidence

-19014000 − 374000 USD

Exact free cash flow: -19388000 USD

Share or cite

The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

21 filings · 977 latest values · 972 originally reported values

Dataset published . Source filing dates and reporting periods are shown separately.

Identifiers: 0002006986, 2006986, ADGM, edgar:2006986

Also known as ADAGIO MEDICAL HOLDINGS, INC., ADAGIO MEDICAL HOLDINGS, INC., Adagio Medical Holdings, Inc., Adagio Medical Holdings, Inc., Aja Holdco, Inc.